Roger E. McLendon, MD - Publications

Affiliations: 
Pathology Duke University, Durham, NC 
Area:
etiology, pathogenesis, and treatment of brain tumors to clinical application
Website:
http://pathology.mc.duke.edu/neuropath/np_faculty_mclendon.htm

261 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, ... ... McLendon RE, et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Research. PMID 31040154 DOI: 10.1158/0008-5472.CAN-18-1010  1
2019 Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology. 78: 57-64. PMID 30500933 DOI: 10.1093/jnen/nly110  1
2018 Diplas BH, Liu H, Yang R, Hansen LJ, Zachem AL, Zhao F, Bigner DD, McLendon RE, Jiao Y, He Y, Waitkus MS, Yan H. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro-Oncology. PMID 30346624 DOI: 10.1093/neuonc/noy167  1
2018 Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 30041899 DOI: 10.1016/j.jocn.2018.06.005  0.68
2018 Tan CL, Landi D, Fuchs H, McLendon RE. Novel case of recurrent intraventricular atypical central neurocytoma with prominent gangliogliomatous differentiation in a 10-year-old boy with 10 years of follow up. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30039530 DOI: 10.1111/neup.12502  0.52
2018 Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, ... McLendon RE, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica. PMID 30019219 DOI: 10.1007/s00401-018-1888-x  0.32
2018 Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, ... McLendon RE, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/NEJMoa1716435  1
2018 Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, ... ... McLendon RE, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications. 9: 2087. PMID 29802247 DOI: 10.1038/s41467-018-04448-6  1
2018 Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy P, Herndon JE, McLendon RE, Keir ST, Archer GE, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29703821 DOI: 10.1158/1078-0432.CCR-17-0126  1
2017 Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojeic I, McLendon RE, Friedman HS, He Y, et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H) induced metabolic liabilities. Cancer Research. PMID 29097607 DOI: 10.1158/0008-5472.CAN-17-1352  1
2017 Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Mclendon R, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.CAN-17-0469  1
2017 Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Research. PMID 28939681 DOI: 10.1158/0008-5472.CAN-17-1018  1
2017 Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Archives of Pathology & Laboratory Medicine. PMID 28829151 DOI: 10.5858/arpa.2016-0580-OA  1
2017 Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1898-1909. PMID 28411277 DOI: 10.1158/1078-0432.CCR-16-2057  0.76
2017 Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, et al. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research : McR. PMID 28148827 DOI: 10.1158/1541-7786.MCR-16-0485  1
2016 Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, Chen C, Xie Q, Mack SC, Wang X, Carcaboso AM, Sloan AE, Ouyang G, McLendon RE, Bian XW, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. The Journal of Experimental Medicine. PMID 27923907 DOI: 10.1084/jem.20151673  0.32
2016 Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269943 DOI: 10.1200/JCO.2015.65.7825  0.32
2016 Strowd RE, Rodriguez FJ, McLendon RE, Vredenburgh JJ, Chance AB, Jallo G, Olivi A, Ahn ES, Blakeley JO. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. American Journal of Medical Genetics. Part A. PMID 26992069 DOI: 10.1002/ajmg.a.37622  0.32
2016 Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet. Oncology. PMID 26976201 DOI: 10.1016/S1470-2045(15)00581-1  1
2016 Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Research. PMID 26896279 DOI: 10.1158/0008-5472.CAN-15-2402  0.32
2016 Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, Wang Q, McLendon RE, Friedman AH, Keir ST, Bigner DD, et al. MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell. 29: 49-60. PMID 26766590 DOI: 10.1016/j.ccell.2015.12.005  1
2016 Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Investigational New Drugs. PMID 26728879 DOI: 10.1007/s10637-015-0318-3  1
2015 Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour E, Pei Y, Moore C, McLendon RE, Huang J, Sampson JH, Wechsler-Reya RJ, Mitchell DA. Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26405194 DOI: 10.1158/1078-0432.CCR-15-0713  0.6
2015 Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/nature14320  0.68
2015 Brat DJ, Cagle PT, Dillon DA, Hattab EM, McLendon RE, Miller MA, Buckner JC. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. Archives of Pathology & Laboratory Medicine. PMID 25642959 DOI: 10.5858/arpa.2014-0588-CP  0.68
2015 Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nature Cell Biology. 17: 170-82. PMID 25580734 DOI: 10.1038/ncb3090  0.68
2015 McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE, Healy P. Prognostic marker analysis in pediatric intracranial ependymomas. Journal of Neuro-Oncology. 122: 255-61. PMID 25563815 DOI: 10.1007/s11060-014-1711-z  0.68
2014 Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang H, Wang XF. miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. The Journal of Clinical Investigation. 124: 4489-502. PMID 25202981 DOI: 10.1172/JCI75284  0.68
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... McLendon RE, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/JCI73093  0.68
2014 Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, ... ... McLendon RE, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics. 46: 726-30. PMID 24880341 DOI: 10.1038/ng.2995  0.68
2014 Babu R, Kranz PG, Agarwal V, McLendon RE, Thomas S, Friedman AH, Bigner DD, Adamson C. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. Journal of Neuro-Oncology. 119: 177-85. PMID 24838419 DOI: 10.1007/s11060-014-1471-9  0.68
2014 Fang X, Huang Z, Zhou W, Wu Q, Sloan AE, Ouyang G, McLendon RE, Yu JS, Rich JN, Bao S. The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (Dayton, Ohio). 32: 2033-47. PMID 24831540 DOI: 10.1002/stem.1730  0.32
2014 Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, ... ... McLendon RE, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048  0.68
2014 Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, ... ... McLendon RE, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Reports. 6: 117-29. PMID 24373972 DOI: 10.1016/j.celrep.2013.11.043  0.68
2014 Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 16: 310-7. PMID 24311632 DOI: 10.1093/neuonc/not154  0.68
2014 Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581  0.68
2014 López GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathology and Applied Neurobiology. 40: 217-20. PMID 23659599 DOI: 10.1111/nan.12060  1
2013 Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 4: 2144-53. PMID 24240169  1
2013 Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, ... ... McLendon RE, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica. 126: 917-29. PMID 24174164 DOI: 10.1007/s00401-013-1198-2  0.68
2013 Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 119: 4180-7. PMID 24104527 DOI: 10.1002/cncr.28343  0.68
2013 Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, ... ... McLendon RE, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genetics. 45: 1141-9. PMID 23917401 DOI: 10.1038/ng.2734  1
2013 Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE, Lehman NL, Miller CR, Schniederjan MJ, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4951-60. PMID 23864165 DOI: 10.1158/1078-0432.CCR-13-0551  0.68
2013 Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4717-27. PMID 23857604 DOI: 10.1158/1078-0432.CCR-12-3891  0.68
2013 Batich KA, William St Clair E, McLendon RE, Sampson JH. Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 1445-8. PMID 23768965 DOI: 10.1016/j.jocn.2013.01.009  0.68
2013 Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE, McLendon RE, Friedman HS. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Journal of Neuro-Oncology. 114: 135-40. PMID 23686298 DOI: 10.1007/s11060-013-1162-y  0.68
2013 Babu R, Hatef J, McLendon RE, Cummings TJ, Sampson JH, Friedman AH, Adamson C. Clinicopathological characteristics and treatment of rhabdoid glioblastoma. Journal of Neurosurgery. 119: 412-9. PMID 23641829 DOI: 10.3171/2013.3.JNS121773  0.68
2013 Park JG, Babu R, Kranz PG, McLendon RE, Adamson C. Intraaxial dermoid cyst of the medulla. Journal of Neurosurgery. 119: 442-5. PMID 23621596 DOI: 10.3171/2013.3.JNS122430  0.68
2013 Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 153: 139-52. PMID 23540695 DOI: 10.1016/j.cell.2013.02.021  0.32
2013 Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... McLendon RE, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1073/pnas.1303607110  0.68
2013 Zhang J, Babu R, McLendon RE, Friedman AH, Adamson C. A comprehensive analysis of 41 patients with rosette-forming glioneuronal tumors of the fourth ventricle. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 335-41. PMID 23375398 DOI: 10.1016/j.jocn.2012.09.003  0.68
2013 Curtis VF, Wang H, Yang P, McLendon RE, Li X, Zhou QY, Wang XF. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. Plos One. 8: e54916. PMID 23372791 DOI: 10.1371/journal.pone.0054916  0.68
2013 Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 900-8. PMID 23363814 DOI: 10.1158/1078-0432.CCR-12-1707  0.68
2013 Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 73: 496-501. PMID 23204232 DOI: 10.1158/0008-5472.CAN-12-2852  0.68
2012 Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, et al. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of Neurology. 72: 766-78. PMID 23280793 DOI: 10.1002/ana.23674  0.68
2012 Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X, Cho YW, Chi JT, Grant GA, McLendon RE, Yan H, Ge K, Papadopoulos N, Bigner DD, He Y. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 109: 17603-8. PMID 23045699 DOI: 10.1073/pnas.1208807109  1
2012 Duong LM, McCarthy BJ, McLendon RE, Dolecek TA, Kruchko C, Douglas LL, Ajani UA. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007. Cancer. 118: 4220-7. PMID 22907705 DOI: 10.1002/cncr.27390  0.68
2012 Blaney SM, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M, Pollack IF, Gururangan S, Geyer R, Phillips P, McLendon RE, Packer R, Goldman S, Banerjee A, Heideman R, et al. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). Journal of Neuro-Oncology. 109: 565-71. PMID 22790443 DOI: 10.1007/s11060-012-0929-x  0.68
2012 Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neuro-Oncology. 109: 63-70. PMID 22535433 DOI: 10.1007/s11060-012-0861-0  0.68
2012 Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology. 108: 499-506. PMID 22407177 DOI: 10.1007/s11060-012-0848-x  0.68
2012 Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. Plos One. 7: e31046. PMID 22383993 DOI: 10.1371/journal.pone.0031046  0.68
2012 Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 21: 155-67. PMID 22340590 DOI: 10.1016/j.ccr.2011.12.021  0.68
2012 Sampson JH, Herndon JE, McLendon RE, Hasselblad V, Asher AL, McGirt MJ, Peterson ED. Clinical data simplified. Journal of Neurosurgery. 116: 346-8; discussion 34. PMID 22054209 DOI: 10.3171/2011.5.JNS11279  0.68
2012 Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107: 155-64. PMID 21986722 DOI: 10.1007/s11060-011-0722-2  0.68
2012 Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. Journal of Neuro-Oncology. 106: 643-9. PMID 21968943 DOI: 10.1007/s11060-011-0709-z  0.68
2012 Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology. 39: 23-34. PMID 21958852 DOI: 10.1016/j.nucmedbio.2011.06.005  1
2012 Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106: 409-15. PMID 21938530 DOI: 10.1007/s11060-011-0687-1  0.68
2011 Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. Plos One. 6: e24807. PMID 21961046 DOI: 10.1371/journal.pone.0024807  0.68
2011 Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, ... McLendon RE, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death & Disease. 2: e200. PMID 21881602 DOI: 10.1038/cddis.2011.80  0.68
2011 McLendon RE, Adekunle A, Rajaram V, Koçak M, Blaney SM. Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Archives of Pathology & Laboratory Medicine. 135: 984-93. PMID 21809989 DOI: 10.5858/2010-0515-OAR1  0.68
2011 Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 118: 3003-12. PMID 21768296 DOI: 10.1182/blood-2011-02-334565  0.68
2011 Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 146: 53-66. PMID 21729780 DOI: 10.1016/j.cell.2011.06.006  0.68
2011 Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117: 5351-8. PMID 21590689 DOI: 10.1002/cncr.26188  0.68
2011 Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 19: 498-511. PMID 21481791 DOI: 10.1016/j.ccr.2011.03.004  0.68
2011 Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146  0.68
2011 Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/neuonc/noq157  0.68
2011 McLendon RE, Rich JN. Glioblastoma Stem Cells: A Neuropathologist's View. Journal of Oncology. 2011: 397195. PMID 21052560 DOI: 10.1155/2011/397195  0.32
2011 Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/s11060-010-0217-6  0.68
2010 Adamson DC, Rasheed BA, McLendon RE, Bigner DD. Central nervous system. Cancer Biomarkers : Section a of Disease Markers. 9: 193-210. PMID 22112477 DOI: 10.3233/CBM-2011-0177  1
2010 Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 1: 265-77. PMID 21113414  0.68
2010 Kuan CT, Chang J, Mansson JE, Li J, Pegram C, Fredman P, McLendon RE, Bigner DD. Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. Bmc Developmental Biology. 10: 114. PMID 21087515 DOI: 10.1186/1471-213X-10-114  1
2010 Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/JCO.2010.28.6963  0.68
2010 Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. Bmc Cancer. 10: 468. PMID 20809959 DOI: 10.1186/1471-2407-10-468  1
2010 Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 12: 1300-10. PMID 20716591 DOI: 10.1093/neuonc/noq099  0.68
2010 Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes & Cancer. 1: 50-61. PMID 20657792 DOI: 10.1177/1947601909356352  0.68
2010 Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/j.bbrc.2010.06.125  1
2010 Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6: 421-32. PMID 20452317 DOI: 10.1016/j.stem.2010.02.018  0.68
2010 Nimjee SM, Powers CJ, McLendon RE, Grant GA, Fuchs HE. Single-stage bilateral choroid plexectomy for choroid plexus papilloma in a patient presenting with high cerebrospinal fluid output. Journal of Neurosurgery. Pediatrics. 5: 342-5. PMID 20367337 DOI: 10.3171/2009.10.PEDS08454  0.68
2010 Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN. Targeting A20 decreases glioma stem cell survival and tumor growth. Plos Biology. 8: e1000319. PMID 20186265 DOI: 10.1371/journal.pbio.1000319  0.68
2010 Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Research. 70: 181-91. PMID 20028867 DOI: 10.1158/0008-5472.CAN-09-2331  0.68
2010 Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon RE, Tucci DL, Sampson JH. Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. Journal of Neuro-Oncology. 98: 427-30. PMID 20020179 DOI: 10.1007/s11060-009-0091-2  0.68
2010 Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, MÃ¥nsson JE, Bigner DD. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochemical and Biophysical Research Communications. 391: 750-5. PMID 19944071 DOI: 10.1016/j.bbrc.2009.11.132  0.68
2010 Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. International Journal of Cancer. Journal International Du Cancer. 127: 598-611. PMID 19937796 DOI: 10.1002/ijc.25062  1
2010 Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer. Journal International Du Cancer. 127: 245-6. PMID 19877121 DOI: 10.1002/ijc.25017  1
2010 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96: 219-30. PMID 19562254 DOI: 10.1007/s11060-009-9950-0  0.68
2009 Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (2005). 28: 389-403. PMID 20025498 DOI: 10.1089/hyb.2009.0049  1
2009 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/sj.bjc.6605412  0.68
2009 Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Research. 69: 9105-11. PMID 19920201 DOI: 10.1158/0008-5472.CAN-09-2775  0.68
2009 Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications. 390: 547-51. PMID 19818334 DOI: 10.1016/j.bbrc.2009.10.001  1
2009 Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (Georgetown, Tex.). 8: 3274-84. PMID 19770585  0.68
2009 Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology (Zurich, Switzerland). 19: 713-23. PMID 19744042 DOI: 10.1111/j.1750-3639.2009.00318.x  0.68
2009 Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (Dayton, Ohio). 27: 2393-404. PMID 19658188 DOI: 10.1002/stem.188  0.68
2009 Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 36: 659-69. PMID 19647172 DOI: 10.1016/j.nucmedbio.2009.04.003  0.68
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 95: 393-400. PMID 19533023 DOI: 10.1007/s11060-009-9937-x  0.68
2009 Waldau B, McLendon RE, Fuchs HE, George TM, Grant GA. Few isolated neurons in hypothalamic hamartomas may cause gelastic seizures. Pediatric Neurosurgery. 45: 225-9. PMID 19521137 DOI: 10.1159/000224620  0.6
2009 Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15: 501-13. PMID 19477429 DOI: 10.1016/j.ccr.2009.03.018  0.68
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 115: 2964-70. PMID 19402172 DOI: 10.1002/cncr.24336  0.68
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007  0.68
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/JCO.2008.18.8417  0.68
2009 Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.CCR-08-2130  0.68
2009 Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 15: 135-47. PMID 19185848 DOI: 10.1016/j.ccr.2008.12.016  0.68
2009 Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathology (Zurich, Switzerland). 19: 439-48. PMID 18652591 DOI: 10.1111/j.1750-3639.2008.00196.x  0.68
2008 Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. Plos One. 3: e3769. PMID 19020659 DOI: 10.1371/journal.pone.0003769  0.68
2008 Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (Dayton, Ohio). 26: 3027-36. PMID 18802038 DOI: 10.1634/stemcells.2007-1073  0.68
2008 Abou-Donia MB, El-Masry EM, Abdel-Rahman AA, McLendon RE, Schiffman SS. Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. Journal of Toxicology and Environmental Health. Part A. 71: 1415-29. PMID 18800291 DOI: 10.1080/15287390802328630  0.68
2008 Ray GT, Agarwal SS, McLendon RE. A recurrent cerebellar lesion in a young boy. Brain Pathology (Zurich, Switzerland). 18: 623-7. PMID 18782180 DOI: 10.1111/j.1750-3639.2008.00216.x  0.68
2008 Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology. 10: 745-51. PMID 18755919 DOI: 10.1215/15228517-2008-044  0.68
2008 Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research. 68: 6043-8. PMID 18676824 DOI: 10.1158/0008-5472.CAN-08-1079  0.68
2008 Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4859-68. PMID 18676759 DOI: 10.1158/1078-0432.CCR-07-4807  0.68
2008 Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, Yachnis AT, Montine TJ, Boyer PJ, Powell SZ, Prayson RA, McLendon RE. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Archives of Pathology & Laboratory Medicine. 132: 993-1007. PMID 18517285 DOI: 10.1043/1543-2165(2008)132[993:SNUARO]2.0.CO;2  0.68
2008 Parisi JE, Miller DV, Boyer PJ, Brat DJ, Cochran EJ, Cohen ML, Demasters BK, Dolinak D, McComb RD, McLendon RE, Powell SZ, Prayson RA, Vinters HV, Yachnis AT. Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. Archives of Pathology & Laboratory Medicine. 132: 907-12. PMID 18517271 DOI: 10.1043/1543-2165(2008)132[907:PFTEOS]2.0.CO;2  0.68
2008 Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012  0.68
2008 Davis FG, Malmer BS, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brännström T, Bruner JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, et al. Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 484-9. PMID 18349266 DOI: 10.1158/1055-9965.EPI-07-0725  0.68
2008 Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 10: 182-9. PMID 18287339 DOI: 10.1215/15228517-2007-053  0.68
2008 Mott RT, Turner KC, Bigner DD, McLendon RE. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. Journal of Neurosurgery. 108: 330-5. PMID 18240930 DOI: 10.3171/JNS/2008/108/2/0330  0.68
2008 Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 271-8. PMID 18182667 DOI: 10.1200/JCO.2007.13.3652  0.64
2008 Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 30-8. PMID 18077533 DOI: 10.2967/jnumed.107.046938  0.68
2008 Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 10: 10-8. PMID 17951512 DOI: 10.1215/15228517-2007-035  0.68
2008 Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica. 115: 261-2. PMID 17926052 DOI: 10.1007/s00401-007-0279-5  0.68
2007 Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5418-25. PMID 17875772 DOI: 10.1158/1078-0432.CCR-07-0418  0.68
2007 McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 34: 405-13. PMID 17499730 DOI: 10.1016/j.nucmedbio.2007.01.009  0.68
2007 Powers CJ, New KC, McLendon RE, Friedman AH, Fuchs HE. Cerebellopontine angle craniopharyngioma: case report and literature review. Pediatric Neurosurgery. 43: 158-63. PMID 17337933 DOI: 10.1159/000098394  0.68
2007 Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology. 83: 53-60. PMID 17245623 DOI: 10.1007/s11060-006-9302-2  0.68
2006 Ochiai H, Pernell CT, Archer GE, Chewning TA, McLendon RE, Friedman HS, Sampson JH. Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurologia Medico-Chirurgica. 46: 485-9; discussion 48. PMID 17062987 DOI: JST.JSTAGE/nmc/46.485  0.68
2006 Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444: 756-60. PMID 17051156 DOI: 10.1038/nature05236  0.68
2006 Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 5: 2531-9. PMID 17041097 DOI: 10.1158/1535-7163.MCT-06-0106  0.68
2006 Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.CAN-06-0284  0.68
2006 Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research. 66: 7843-8. PMID 16912155 DOI: 10.1158/0008-5472.CAN-06-1010  0.68
2006 Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299  0.68
2006 Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.CCR-05-2215  0.68
2006 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 115-22. PMID 16382120 DOI: 10.1200/JCO.2005.03.4082  0.68
2006 Chintagumpala MM, Friedman HS, Stewart CF, Kepner J, McLendon RE, Modrich PL, McCluggage C, Burger P, Holmes E, Thompson S, Rutka J, Michalski J, Woo S, Blaney SM, Kun LE, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. Journal of Neuro-Oncology. 77: 193-8. PMID 16314955 DOI: 10.1007/s11060-005-9024-x  0.68
2005 Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9359-68. PMID 16361636 DOI: 10.1200/JCO.2005.03.2185  0.68
2005 Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8145-57. PMID 16299247 DOI: 10.1158/1078-0432.CCR-05-0319  1
2005 Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/JCO.2005.06.502  0.68
2005 McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 104: 1693-9. PMID 16116609 DOI: 10.1002/cncr.21362  0.68
2005 Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1042-51. PMID 15937318  0.68
2005 Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research. 65: 4051-8. PMID 15899794 DOI: 10.1158/0008-5472.CAN-04-3936  0.68
2005 Crain BJ, Alston SR, Bruch LA, Hamilton RL, McLendon RE, Rhodes CH, Tihan T, Weidenheim KM. Accreditation council for graduate medical education (ACGME) competencies in neuropathology training. Journal of Neuropathology and Experimental Neurology. 64: 273-9. PMID 15835263  0.68
2005 Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research. 65: 919-24. PMID 15705891  0.68
2005 Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589  0.68
2005 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358  0.68
2004 Alexander RT, McLendon RE, Cummings TJ. Meningioma with eosinophilic granular inclusions. Clinical Neuropathology. 23: 292-7. PMID 15584214  0.68
2004 Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 64: 5048-50. PMID 15289301 DOI: 10.1158/0008-5472.CAN-04-1170  0.68
2004 Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics : Jmd. 6: 166-79. PMID 15269292 DOI: 10.1016/S1525-1578(10)60507-7  0.68
2004 McLendon RE, Rasheed A, Wiltshire R, Herndon J. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 17: 604-5. PMID 15105803 DOI: 10.1038/modpathol.3800077  0.64
2004 Cummings TJ, George TM, Fuchs HE, McLendon RE. The pathology of extracranial scalp and skull masses in young children. Clinical Neuropathology. 23: 34-43. PMID 14986932  0.6
2004 Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/JCO.2004.08.110  0.68
2003 Scheuner D, Gromeier M, Davies MV, Dorner AJ, Song B, Patel RV, Wimmer EJ, McLendon RE, Kaufman RJ. The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis. Virology. 317: 263-74. PMID 14698665 DOI: 10.1016/j.virol.2003.08.010  0.68
2003 Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5514-20. PMID 14654531  0.68
2003 Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809  0.68
2003 Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2187-91. PMID 12775745 DOI: 10.1200/JCO.2003.10.096  0.68
2003 George DH, Scheithauer BW, Aker FV, Kurtin PJ, Burger PC, Cameselle-Teijeiro J, McLendon RE, Parisi JE, Paulus W, Roggendorf W, Sotelo C. Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. The American Journal of Surgical Pathology. 27: 487-93. PMID 12657933 DOI: 10.1097/00000478-200304000-00008  0.68
2003 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/JCO.2003.01.009  0.68
2002 Heimberger AB, Wiltshire RN, Bronec R, McLendon RE, Cummings TJ. Biphasic malignant meningioma: a comparative genomic hybridization study. Clinical Neuropathology. 21: 258-64. PMID 12489674  0.56
2002 Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3496-502. PMID 12429640  0.68
2002 Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of Radiation Oncology, Biology, Physics. 54: 1259-75. PMID 12419456  1
2002 Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 94: 2688-97. PMID 12173338 DOI: 10.1002/cncr.10544  0.68
2002 Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/JCO.2002.09.084  0.68
2002 Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Archives of Pathology & Laboratory Medicine. 126: 540-4. PMID 11958658 DOI: 10.1043/0003-9985(2002)126<0540:MAMOAI>2.0.CO;2  0.68
2002 Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology. 4: 102-8. PMID 11916501  0.76
2002 Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro-Oncology. 4: 75-85. PMID 11916498 DOI: 10.1215/S1522851701000059  0.68
2002 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/JCO.20.5.1389  0.68
2002 Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024  0.68
2001 Morgan MA, Enterline DS, Fukushima T, McLendon RE, Cummings TJ. Endodermal cyst of the oculomotor nerve. Neuroradiology. 43: 1063-6. PMID 11792045  0.56
2001 Eastwood JD, Turner DA, McLendon RE, Provenzale JM. Diffusion-weighted MR imaging in a patient with spinal meningioma. Ajr. American Journal of Roentgenology. 177: 1479-81. PMID 11717111 DOI: 10.2214/ajr.177.6.1771479  0.68
2001 Cummings TJ, Burchette JL, McLendon RE. CD34 and dural fibroblasts: the relationship to solitary fibrous tumor and meningioma. Acta Neuropathologica. 102: 349-54. PMID 11603810  0.56
2001 Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 3: 246-50. PMID 11584894 DOI: 10.1215/S1522851700000703  0.68
2001 Cummings TJ, Ebert RH, Provenzale J, McLendon RE. March 2000: A 16 year old female with a cerebellar mass. Brain Pathology (Zurich, Switzerland). 11: 391-3. PMID 11414481  0.56
2001 Winkelstein BA, McLendon RE, Barbir A, Myers BS. An anatomical investigation of the human cervical facet capsule, quantifying muscle insertion area. Journal of Anatomy. 198: 455-61. PMID 11327207 DOI: 10.1017/S0021878201007518  0.68
2001 Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Research. 61: 3556-60. PMID 11325817  0.68
2001 Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE. Ham56-immunoreactive macrophages in untreated infiltrating gliomas. Archives of Pathology & Laboratory Medicine. 125: 637-41. PMID 11300934 DOI: 10.1043/0003-9985(2001)125<0637:HIMIUI>2.0.CO;2  0.68
2001 Cummings TJ, Bentley RC, McLendon RE. Pathologic quiz case: pituitary mass in a 48-year-old woman. Archives of Pathology & Laboratory Medicine. 125: 299-300. PMID 11175658 DOI: 10.1043/0003-9985(2001)125<0299:PQCPMI>2.0.CO;2  0.56
2000 Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3862-72. PMID 11078500  0.68
2000 Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4148-53. PMID 11051269  0.68
2000 Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3522-8. PMID 11032594  0.68
2000 Cummings TJ, Gong JZ, Friedman AH, McLendon RE. Castleman's disease confined to the leptomeninges. Annals of Clinical and Laboratory Science. 30: 278-82. PMID 10945568  0.76
2000 McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 48: 1103-10. PMID 10898803  0.68
2000 Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathologica. 99: 563-70. PMID 10805102  0.68
2000 Cummings TJ, McLendon RE. Pineal epidermoid cysts. Journal of Neurosurgery. 92: 909-10. PMID 10794322  0.56
2000 Aldosari N, Rasheed BK, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathologica. 99: 345-51. PMID 10787031  0.68
2000 Cummings TJ, Madden JF, Gray L, Friedman AH, McLendon RE. Parasitic lesion of the insula suggesting cerebral sparganosis: case report. Neuroradiology. 42: 206-8. PMID 10772144  0.68
2000 Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation Oncology, Biology, Physics. 46: 947-58. PMID 10705017  1
2000 Provenzale JM, Ali U, Barboriak DP, Kallmes DF, Delong DM, McLendon RE. Comparison of patient age with MR imaging features of gangliogliomas. Ajr. American Journal of Roentgenology. 174: 859-62. PMID 10701639 DOI: 10.2214/ajr.174.3.1740859  0.68
2000 Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology. 103: 16-25. PMID 10674985 DOI: 10.1016/S0165-5728(99)00172-1  0.68
1999 Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro-Oncology. 1: 52-60. PMID 11550302  0.68
1999 Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology. 44: 233-41. PMID 10720203 DOI: 10.1023/A:1006304424346  0.68
1999 Nuckols JD, Liu K, Burchette JL, McLendon RE, Traweek ST. Primary central nervous system lymphomas: a 30-year experience at a single institution. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 12: 1167-73. PMID 10619271  0.68
1999 Provenzale JM, Arata MA, Turkington TG, McLendon RE, Coleman RE. Gangliogliomas: characterization by registered positron emission tomography-MR images. Ajr. American Journal of Roentgenology. 172: 1103-7. PMID 10587156 DOI: 10.2214/ajr.172.4.10587156  0.56
1999 Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ. A public database for gene expression in human cancers. Cancer Research. 59: 5403-7. PMID 10554005  0.68
1999 Chu CT, Howell DN, Morgenlander JC, Hulette CM, McLendon RE, Miller SE. Electron microscopic diagnosis of human flavivirus encephalitis: use of confocal microscopy as an aid. The American Journal of Surgical Pathology. 23: 1217-26. PMID 10524522  0.56
1999 Cummings TJ, Bentley RC, Gray L, Check WE, Lanier TE, McLendon RE. Meningioma of the fourth ventricle. Clinical Neuropathology. 18: 265-9. PMID 10505436  0.68
1999 Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 2646-52. PMID 10499644  0.68
1999 McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 45: 491-9. PMID 10487576 DOI: 10.1016/S0360-3016(99)00206-0  0.68
1999 Cummings TJ, Hulette CM, Longee DC, Bottom KS, McLendon RE, Chu CT. Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Clinical Neuropathology. 18: 190-7. PMID 10442461  0.56
1999 Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. The American Journal of Pathology. 155: 375-86. PMID 10433931 DOI: 10.1016/S0002-9440(10)65134-6  0.68
1999 Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755  0.68
1999 Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1516-25. PMID 10334539  0.68
1999 Dash RC, Provenzale JM, McComb RD, Perry DA, Longee DC, McLendon RE. Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. Archives of Pathology & Laboratory Medicine. 123: 342-5. PMID 10320149 DOI: 10.1043/0003-9985(1999)123<0342:MSGGCG>2.0.CO;2  0.68
1999 Dodd LG, Marom EM, Dash RC, Matthews MR, McLendon RE. Fine-needle aspiration cytology of "ancient" schwannoma. Diagnostic Cytopathology. 20: 307-11. PMID 10319234 DOI: 10.1002/(SICI)1097-0339(199905)20:5<307::AID-DC12>3.0.CO;2-F  0.56
1999 Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I, Friedman AH. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer. 85: 1160-5. PMID 10091802 DOI: 10.1002/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F  0.76
1999 McLendon RE, Friedman HS, Fuchs HE, Kun LE, Bigner SH. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology. 34: 154-62. PMID 10064395 DOI: 10.1046/j.1365-2559.1999.00577.x  0.68
1998 Moghrabi A, Friedman HS, Ashley DM, Bottom KS, Kerby T, Stewart E, Bruggers C, Provenzale JM, Champagne M, Hershon L, Watral M, Ryan J, Rasheed K, Lovell S, Korones D, ... ... McLendon RE, et al. Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas. Neurosurgical Focus. 4: e3. PMID 17168503  0.76
1998 Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030  0.68
1998 Koen JL, McLendon RE, George TM. Intradural spinal teratoma: evidence for a dysembryogenic origin. Report of four cases. Journal of Neurosurgery. 89: 844-51. PMID 9817426 DOI: 10.3171/jns.1998.89.5.0844  0.68
1998 Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277  1
1998 Komori T, Scheithauer BW, Anthony DC, Rosenblum MK, McLendon RE, Scott RM, Okazaki H, Kobayashi M. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. The American Journal of Surgical Pathology. 22: 1171-83. PMID 9777979 DOI: 10.1097/00000478-199810000-00002  0.68
1998 Marriott CJ, Thorstad W, Akabani G, Brown MT, McLendon RE, Hanson MW, Coleman RE. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 39: 1376-80. PMID 9708511  0.68
1998 Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2202-12. PMID 9626222  0.68
1998 McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 78: 643-4. PMID 9605190  0.68
1998 Slavik T, Bentley RC, Gray L, Fuchs HE, McLendon RE. Solitary fibrous tumor of the meninges occurring after irradiation of a mixed germ cell tumor of the pineal gland. Clinical Neuropathology. 17: 55-60. PMID 9496542  0.6
1998 McCowage GB, Friedman HS, Moghrabi A, Kerby T, Ferrell L, Stewart E, Duncan-Brown M, Fuchs HE, Tien R, McLendon RE, Meier L, Kurtzberg J, Ashley D, Colvin OM, Longee DC. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Medical and Pediatric Oncology. 30: 75-80. PMID 9403013 DOI: 10.1002/(SICI)1096-911X(199802)30:2<75::AID-MPO1>3.0.CO;2-X  0.68
1997 Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research. 57: 4187-90. PMID 9331072  0.68
1997 Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Research. 57: 4130-40. PMID 9307304  1
1997 Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS. Chromosomal characteristics of childhood brain tumors. Cancer Genetics and Cytogenetics. 97: 125-34. PMID 9283596 DOI: 10.1016/S0165-4608(96)00404-9  0.68
1997 McLendon RE, Bentley RC, Parisi JE, Tien RD, Harrison JC, Tarbell NJ, Billitt AL, Gualtieri RJ, Friedman HS. Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. Archives of Pathology & Laboratory Medicine. 121: 485-92. PMID 9167602  0.68
1997 Provenzale JM, Schaefer P, Traweek ST, Ferry J, Moore JO, Friedman AH, McLendon RE. Craniocerebral plasmacytoma: MR features. Ajnr. American Journal of Neuroradiology. 18: 389-92. PMID 9111682  0.76
1997 Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39: 307-16. PMID 9025771 DOI: 10.1007/s002800050577  0.68
1997 Ashraf R, Bentley RC, Awan AN, McLendon RE, Ragozzino MW. Implantation metastasis of primary malignant rhabdoid tumor of the brain in an adult (one case report). Medical and Pediatric Oncology. 28: 223-7. PMID 9024522 DOI: 10.1002/(SICI)1096-911X(199703)28:3<223::AID-MPO14>3.0.CO;2-F  0.68
1996 Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 2: 963-72. PMID 9816257  0.68
1996 Blaeker H, Rasheed BK, McLendon RE, Friedman HS, Batra SK, Fuchs HE, Bigner SH. Microsatellite analysis of childhood brain tumors. Genes, Chromosomes & Cancer. 15: 54-63. PMID 8824726 DOI: 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.0.CO;2-3  0.68
1996 McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 35: 69-80. PMID 8641929  0.68
1996 McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS. Production and characterization of two ependymoma xenografts. Journal of Neuropathology and Experimental Neurology. 55: 540-8. PMID 8627345  0.68
1996 Towfighi J, Salam MM, McLendon RE, Powers S, Page RB. Ganglion cell-containing tumors of the pituitary gland. Archives of Pathology & Laboratory Medicine. 120: 369-77. PMID 8619749  0.68
1995 Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE, Pastan IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1545-55. PMID 9815955  0.68
1995 Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 15: 244-56. PMID 8586461 DOI: 10.1002/glia.440150306  0.68
1995 Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH. Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology. 24: 39-45. PMID 8523074 DOI: 10.1007/BF01052657  0.68
1995 Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. Journal of Neuro-Oncology. 24: 109-22. PMID 8523067 DOI: 10.1007/BF01052668  0.68
1995 Lee VS, Provenzale JM, Fuchs HE, Osumi A, McLendon RE. Post-traumatic epidermoid cyst: CT appearance. Journal of Computer Assisted Tomography. 19: 153-5. PMID 7822537  0.6
1995 Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW. A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery. 36: 976-84; discussion 9. PMID 7791991  1
1995 Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 10: 2243-6. PMID 7784070  0.68
1995 Hitchcock MG, Ellington KS, Friedman AH, Provenzaie JM, McLendon RE. Shadow cells in an intracranial dermoid cyst. Archives of Pathology & Laboratory Medicine. 119: 371-3. PMID 7726731  0.76
1995 Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proceedings of the National Academy of Sciences of the United States of America. 92: 2765-9. PMID 7708720  0.68
1995 Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD. Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Research. 55: 3803-9. PMID 7641197  0.68
1995 Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Research. 55: 3140-8. PMID 7606735  0.68
1995 Felsberg GJ, Tien RD, McLendon RE. Frontoethmoidal giant cell reparative granuloma. Ajnr. American Journal of Neuroradiology. 16: 1551-4. PMID 7484655  0.68
1994 Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH. Alterations of the TP53 gene in human gliomas. Cancer Research. 54: 1324-30. PMID 8118823  0.68
1994 Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Research. 54: 4719-25. PMID 8062270  0.68
1994 Friedman HS, Archer GE, McLendon RE, Schuster JM, Colvin OM, Guaspari A, Blum R, Savina PA, Fuchs HE, Bigner DD. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Research. 54: 4710-4. PMID 8062269  0.68
1994 McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathology (Zurich, Switzerland). 4: 221-8. PMID 7952263  1
1994 Osumi AK, Mclendon RE, Tien RD, Friedman HS, Graham M, Hockenberger B, Halperin EC, Oakes WJ. Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma. Clinical Neuropathology. 13: 281-5. PMID 7805312  0.68
1993 Schuster JM, Friedman HS, Archer GE, Fuchs HE, McLendon RE, Colvin OM, Bigner DD. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Research. 53: 2338-43. PMID 8485721  0.68
1993 Wikstrand CJ, Longee DC, McLendon RE, Fuller GN, Friedman HS, Fredman P, Svennerholm L, Bigner DD. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Research. 53: 120-6. PMID 8416736  1
1988 McLendon RE, Oakes WJ, Heinz ER, Yeates AE, Burger PC. Adipose tissue in the filum terminale: a computed tomographic finding that may indicate tethering of the spinal cord. Neurosurgery. 22: 873-6. PMID 2967925  0.72
1987 Woodruff WW, Djang WT, McLendon RE, Heinz ER, Voorhees DR. Intracerebral malignant melanoma: high-field-strength MR imaging. Radiology. 165: 209-13. PMID 3628773 DOI: 10.1148/radiology.165.1.3628773  0.68
1987 Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, de Tribolet N, Bullard DE, Zalutsky MR, Bigner DD. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. Journal of Neuroimmunology. 15: 37-56. PMID 3571486  1
1987 Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE. Clinicopathologic correlations in the oligodendroglioma. Cancer. 59: 1345-52. PMID 3545437  0.72
1986 Woodruff WW, Yeates AE, McLendon RE. Perineural tumor extension to the cavernous sinus from superficial facial carcinoma: CT manifestations. Radiology. 161: 395-9. PMID 3763908 DOI: 10.1148/radiology.161.2.3763908  0.32
1986 Wikstrand CJ, McLendon RE, Bullard DE, Fredman P, Svennerholm L, Bigner DD. Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. Cancer Research. 46: 5933-40. PMID 3756930  1
1986 McLendon RE, Burger PC, Pegram CN, Eng LF, Bigner DD. The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues. Journal of Neuropathology and Experimental Neurology. 45: 692-703. PMID 3534145  1
1985 McLendon RE, Crain BJ, Oakes WJ, Burger PC. Cerebral polygyria in the Chiari Type II (Arnold-Chiari) malformation. Clinical Neuropathology. 4: 200-5. PMID 4064385  0.72
1985 McLendon RE, Robinson JS, Chambers DB, Grufferman S, Burger PC. The glioblastoma multiforme in Georgia, 1977-1981. Cancer. 56: 894-7. PMID 2990658  0.72
Show low-probability matches.